"Prospective, Double-blind, Multicenter, Placebo-controlled, Randomized, Comparative Clinical Study of the Efficacy and Safety of the Drug Neovasculgen® Lyophilisate for the Preparation of a Solution for Intramuscular Administration 1.2 mg", Manufacturer Federal State Budgetary Institution "NMITs of Hematology" of the Ministry of Health of the Russian Federation, Russia in Patients With Diabetic Foot Syndrome"
Latest Information Update: 11 Feb 2026
At a glance
- Drugs Vascular endothelial growth factor gene therapy (Primary)
- Indications Diabetic foot ulcer
- Focus Registrational; Therapeutic Use
- Sponsors JSC NextGen
Most Recent Events
- 11 Feb 2026 New trial record